BDX Becton Dickinson & Co (BDX) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000010795
Form 144 · 7
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
692
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $9.8M priced
What the filings say about BDX
Insiders, 180 days
-$2.0M net sold
4 sellers · 27% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 2 sold
Latest: sale, 2026-05-21
Planned sales (Form 144), 90 days
$1.8M
7 notices
Becton Dickinson & Co insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BECTON DICKINSON & CO insiders sold a net $2.0M of stock across 91 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Sep 28, 2026.
- The trade is 0.4% of the 19,568 shares held after it.
- No other insider sold within 30 days.
- 692 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Revenue Officer Feld Michael sold about $15.1K of BDX under a 10b5-1 plan on Oct 26, 2026; 692 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Aug 26, 2026.
- The trade is 0.4% of the 19,644 shares held after it.
- No other insider sold within 30 days.
- 692 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Revenue Officer Feld Michael sold about $14.0K of BDX under a 10b5-1 plan on Sep 28, 2026; 692 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Jul 27, 2026.
- The trade is 0.8% of the 19,720 shares held after it.
- 2 other insiders sold within 30 days.
- 692 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Revenue Officer Feld Michael sold about $31.1K of BDX under a 10b5-1 plan on Aug 26, 2026; 2 other insiders sold within 30 days and 692 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 1, 2026.
- The trade is 3.8% of the 110,163 shares held after it.
- 2 other insiders sold within 30 days.
- 692 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, CEO and President Polen Thomas E Jr sold about $768.1K of BDX on Aug 13, 2026, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 692 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Dec 9, 2024.
- The trade is 16.4% of the 14,856 shares held after it.
- 2 other insiders sold within 30 days.
- 692 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP and President, EMEA Goette Roland sold about $440.9K of BDX on Aug 11, 2026, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 692 funds added in the latest 13F quarter.91 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.0M over 180 days
-$1.3M over 90 days
below 68% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
692 funds bought in last quarter
more than 97% of Medical Devices
Revenue
+8.2% year over year
below 55% of Medical Devices
Margin
7.7% net margin
more than 78% of Medical Devices
Buybacks
$2.2B repurchased, FY to 2026-06-30
more than 97% of Medical Devices
Short interest
3.6% of the float short (float per yahoo 2026-10-26) · 4.9 days to cover · settled 2026-09-30
more than 52% of Medical Devices
What changed in the last 30 days
Oct 27EVP, Chief Revenue Officer Feld Michael sold $29.0K under a 10b5-1 plan (2 trades, Sep 28 to Oct 26)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 26Officer MICHAEL FELD filed to sell $15.1K by Oct 26 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 28Officer MICHAEL FELD filed to sell $14.0K by Sep 28 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch BDX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+35.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BDX: institutional holders (13F)
13F holdings, latest reported quarter
27,630,670 sh
$4.2B
24,592,166 sh
$3.7B
17,987,834 sh
$2.7B
8,650,967 sh
$2.5B
15,000,064 sh
$2.3B
Congress trades in BDX
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-05-21 · disclosed 28 days later
$1,001 - $15,000
Sold 2026-03-17 · disclosed 17 days later
$15,001 - $50,000
Sold 2025-06-24 · disclosed 50 days later
$1,001 - $15,000
Bought 2025-06-17 · disclosed 57 days later
$1,001 - $15,000
Bought 2025-05-15 · disclosed 25 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BDX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MICHAEL FELD
Filed 2026-10-26
$15.1K
MICHAEL FELD
Filed 2026-09-28
$14.0K
MICHAEL FELD
Filed 2026-08-26
$31.3K
RICHARD BYRD
Filed 2026-08-20
$250.0K
THOMAS POLEN
Filed 2026-08-13
$762.2K
BDX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
First Eagle Rising Dividend Fund
$23.0M position · as of 2026-07-31
4.8%
iShares U.S. Medical Devices ETF
$139.9M position · as of 2026-06-30
4.6%
Oakmark Global Select Fund
$37.6M position · as of 2026-06-30
4.6%
Clarkston Fund
$1.4M position · as of 2026-06-30
4.5%
FMI Large Cap Fund
$43.9M position · as of 2026-06-30
4.1%
FMI Global Fund
$438.9K position · as of 2026-06-30
3.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Thomas E. Polen
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$17.1M
$3.5M
$4.3M
-11%
+30%
2024
$17.3M
$9.5M
$4.0M
+13%
+27%
2023
$17.3M
$29.8M
$4.5M
+19%
+2%
2022
$16.7M
$15.0M
$4.2M
+1%
-10%
2021
$14.2M
$16.7M
$3.7M
+7%
+27%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.0M sold by insiders over 180 days, 692 funds added last quarter, $1.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
BDX financials
Revenue growth
+8.2%
XBRL, annual
Net margin
7.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$20.8B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BDX
| FY Sep 2025 | $21.8B |
| FY Sep 2024 | $20.2B |
| FY Sep 2023 | $19.4B |
| FY Sep 2022 | n/a |
| FY Sep 2021 | $20.2B |
| Jun 2026 | $5.0B |
| Mar 2026 | $4.7B |
| Dec 2025 | $5.3B |
| Sep 2025 | $5.9B |
| Jun 2025 | $5.5B |
| Mar 2025 | $5.3B |
| Dec 2024 | $5.2B |
| Sep 2024 | $5.4B |
At each fiscal year end
Single quarter
Net margin, TTM
+4.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BDX
| FY Sep 2025 | +7.7% |
| FY Sep 2024 | +8.4% |
| FY Sep 2023 | +7.7% |
| FY Sep 2022 | n/a |
| FY Sep 2021 | +10.3% |
| Jun 2026 | +7.6% |
| Mar 2026 | -6.6% |
| Dec 2025 | +7.3% |
| Sep 2025 | +8.4% |
| Jun 2025 | +10.4% |
| Mar 2025 | +5.8% |
| Dec 2024 | +5.9% |
| Sep 2024 | +7.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM BDX
| FY Sep 2025 | n/a |
| FY Sep 2024 | $2.3B |
| FY Sep 2023 | $2.2B |
| FY Sep 2022 | $2.1B |
| FY Sep 2021 | $3.5B |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $549.0M |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $588.0M |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.69x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity BDX
| FY Sep 2025 | 0.76x |
| FY Sep 2024 | 0.78x |
| FY Sep 2023 | 0.62x |
| FY Sep 2022 | 0.64x |
| FY Sep 2021 | 0.74x |
| Jun 2026 | 0.69x |
| Mar 2026 | 0.72x |
| Dec 2025 | 0.77x |
| Sep 2025 | 0.76x |
| Jun 2025 | 0.76x |
| Mar 2025 | 0.76x |
| Dec 2024 | 0.74x |
| Sep 2024 | 0.78x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt BDX
| FY Sep 2025 | n/a |
| FY Sep 2024 | 0.15x |
| FY Sep 2023 | 0.19x |
| FY Sep 2022 | 0.19x |
| FY Sep 2021 | 0.26x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 0.15x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+3.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BDX
| FY Sep 2025 | +6.5% |
| FY Sep 2024 | +6.6% |
| FY Sep 2023 | +5.8% |
| FY Sep 2022 | +7.3% |
| FY Sep 2021 | +8.8% |
| Jun 2026 | +3.8% |
| Mar 2026 | +4.6% |
| Dec 2025 | +7.0% |
| Sep 2025 | +6.5% |
| Jun 2025 | +6.2% |
| Mar 2025 | +5.9% |
| Dec 2024 | +6.8% |
| Sep 2024 | +6.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BDX
| FY Sep 2025 | +3.0% |
| FY Sep 2024 | +3.1% |
| FY Sep 2023 | +2.8% |
| FY Sep 2022 | +3.3% |
| FY Sep 2021 | +3.9% |
| Jun 2026 | +1.8% |
| Mar 2026 | +2.2% |
| Dec 2025 | +3.2% |
| Sep 2025 | +3.0% |
| Jun 2025 | +2.9% |
| Mar 2025 | +2.8% |
| Dec 2024 | +3.2% |
| Sep 2024 | +3.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital BDX
| FY Sep 2025 | n/a |
| FY Sep 2024 | +4.6% |
| FY Sep 2023 | +4.8% |
| FY Sep 2022 | +5.4% |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | +4.3% |
| Mar 2025 | +4.2% |
| Dec 2024 | +4.9% |
| Sep 2024 | +4.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed BDX
| FY Sep 2025 | n/a |
| FY Sep 2024 | +5.1% |
| FY Sep 2023 | +4.6% |
| FY Sep 2022 | +4.9% |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | +4.6% |
| Mar 2025 | +4.4% |
| Dec 2024 | +5.3% |
| Sep 2024 | +5.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
59.15x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing BDX
| FY Sep 2025 | 25.24x |
| FY Sep 2024 | 32.35x |
| FY Sep 2023 | 41.23x |
| FY Sep 2022 | 29.74x |
| FY Sep 2021 | 27.48x |
| Jun 2026 | 45.58x |
| Mar 2026 | 39.81x |
| Dec 2025 | 24.89x |
| Sep 2025 | 25.24x |
| Jun 2025 | 24.71x |
| Mar 2025 | 34.90x |
| Dec 2024 | 30.03x |
| Sep 2024 | 32.35x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$69.6B
market value at close 2026-10-26 on 2026-06-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value BDX
| FY Sep 2025 | $60.8B |
| FY Sep 2024 | $73.2B |
| FY Sep 2023 | $73.4B |
| FY Sep 2022 | $65.0B |
| FY Sep 2021 | $69.5B |
| Jun 2026 | $57.3B |
| Mar 2026 | $59.8B |
| Dec 2025 | $62.2B |
| Sep 2025 | $60.8B |
| Jun 2025 | $57.4B |
| Mar 2025 | $70.2B |
| Dec 2024 | $69.3B |
| Sep 2024 | $73.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield BDX
| FY Sep 2025 | n/a |
| FY Sep 2024 | +4.2% |
| FY Sep 2023 | +3.7% |
| FY Sep 2022 | +4.1% |
| FY Sep 2021 | +6.4% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +4.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -39%, PEG needs growth
PEG, trailing BDX
| FY Sep 2025 | n/a |
| FY Sep 2024 | 1.71x |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | 0.18x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 7.78x |
| Sep 2025 | n/a |
| Jun 2025 | 1.84x |
| Mar 2025 | 2.42x |
| Dec 2024 | 0.72x |
| Sep 2024 | 1.71x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-09 | |
|---|---|---|---|---|
| Revenue | $21.8B | $20.2B | $19.4B | $18.9B |
| Operating income | $2.6B | $2.4B | $2.1B | $2.3B |
| Net income | $1.7B | $1.7B | $1.5B | $1.8B |
| EPS (diluted) | 5.82 | 5.86 | 4.94 | 5.88 |
| Cash | $567.0M | $1.7B | $1.4B | $1.0B |
| Long-term debt | $17.6B | $17.9B | $14.7B | $13.9B |
| Buybacks | $1.0B | $500.0M | $0 | $500.0M |
| Dividends paid | $1.2B | $1.1B | $1.1B | $1.1B |
SEC XBRL, fiscal years, as known on 2026-10-27
BDX Stock Sonar score 6/7 axes
Find similar shapesCompareBDX ranks highest on profitability (73rd percentile) and institutional and government (50th), and lowest on insider conviction (15th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BDX filings, in plain words
Are Becton Dickinson & Co insiders buying or selling BDX?
In the 180 days to 2026-10-27, Becton Dickinson & Co insiders were net sellers, a net $2.0M across purchases and sales reported on Form 4, by 4 sellers.
Have members of Congress traded BDX?
Yes. In the year to 2026-10-27, 0 House members disclosed buying BDX and 2 House members disclosed selling it; the latest on record is a sale by Thomas H. Kean dated 2026-05-21.
Are there planned insider sales of BDX?
Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $1.8M of stock; the latest, by MICHAEL FELD, was filed 2026-10-26.
Read the full summary
In the 180 days to 2026-10-27, Becton Dickinson & Co insiders were net sellers of BDX, a net $2.0M across purchases and sales reported on Form 4 by 4 sellers. 27% of the 11 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 0 members of Congress disclosed buying BDX and 2 members disclosed selling it; the latest on record is a sale by Thomas H. Kean dated 2026-05-21. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $1.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
